Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises the price target from $24 to $25.
Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises the price target from $24 to $25.